Last reviewed · How we verify

Lumoxiti — Competitive Intelligence Brief

Lumoxiti (MOXETUMOMAB PASUDOTOX) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Oncology.

marketed B-cell receptor CD22 Oncology Antibody drug conjugate Live · refreshed every 30 min

Target snapshot

Lumoxiti (MOXETUMOMAB PASUDOTOX) — AstraZeneca.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Lumoxiti TARGET MOXETUMOMAB PASUDOTOX AstraZeneca marketed B-cell receptor CD22 2018-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lumoxiti — Competitive Intelligence Brief. https://druglandscape.com/ci/moxetumomab-pasudotox. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: